| scholarly article | Q13442814 |
| P2093 | author name string | M G Morgese | |
| T Cassano | |||
| V Cuomo | |||
| L Ferraro | |||
| A Giuffrida | |||
| L Laconca | |||
| P Dipasquale | |||
| S Gaetani | |||
| T Antonelli | |||
| T Macheda | |||
| P2860 | cites work | A golgi analysis of cortical pyramidal cells in the unilateral parkinson rat: absence of change in the affected hemisphere vs hypertrophy in the intact hemisphere | Q80860610 |
| Long-term depression of cortico-striatal synaptic transmission by DHPG depends on endocannabinoid release and nitric oxide synthesis | Q81295058 | ||
| The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study | Q28207211 | ||
| "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy | Q28317866 | ||
| Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons | Q28363375 | ||
| Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice | Q28469322 | ||
| D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons | Q29619181 | ||
| L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function | Q30837835 | ||
| Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. | Q31039577 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration | Q33266058 | ||
| Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia | Q33280726 | ||
| Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels | Q33996977 | ||
| Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms | Q34326908 | ||
| Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum | Q34605794 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats | Q35041427 | ||
| CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 | ||
| Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia | Q35255416 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step | Q36300113 | ||
| Distribution of cannabinoid receptors in the central and peripheral nervous system. | Q36441196 | ||
| Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease | Q36586033 | ||
| Advances in understanding L-DOPA-induced dyskinesia | Q37097551 | ||
| Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes | Q40103549 | ||
| The basal ganglia and adaptive motor control | Q40706589 | ||
| Role of cyclic AMP in the actions of cannabinoid receptors | Q41090638 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model | Q41738298 | ||
| Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice | Q42168324 | ||
| A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function | Q42463405 | ||
| Reciprocal dopamine-glutamate modulation of release in the basal ganglia | Q42466023 | ||
| Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease | Q42466915 | ||
| Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. | Q42492136 | ||
| Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. | Q42507026 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. | Q42539090 | ||
| Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. | Q43621342 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 | ||
| Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model | Q44013385 | ||
| Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse | Q44084440 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals | Q44905912 | ||
| Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury. | Q46004616 | ||
| Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. | Q46279749 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus | Q46490171 | ||
| Epileptogenesis and chronic seizures in a mouse model of temporal lobe epilepsy are associated with distinct EEG patterns and selective neurochemical alterations in the contralateral hippocampus | Q46495121 | ||
| Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. | Q46932814 | ||
| Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats | Q46963093 | ||
| The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus | Q46983260 | ||
| Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine | Q46986296 | ||
| Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study | Q46988378 | ||
| Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 | ||
| Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease | Q48243272 | ||
| Different levodopa actions on the extracellular dopamine pools in the rat striatum | Q48363512 | ||
| Changes in dopamine D2 receptors and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake in the brain of 6-hydroxydopamine-lesioned rats | Q48447153 | ||
| L-DOPA inhibits depolarization-induced [3H]GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like receptors. | Q48516394 | ||
| Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. | Q48523125 | ||
| Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance | Q48607608 | ||
| Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. | Q48631827 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| Functional interactions between glutamate and dopamine in the rat striatum. | Q52215285 | ||
| Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. | Q53916968 | ||
| CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. | Q54579193 | ||
| Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 | ||
| D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy | Q70068571 | ||
| Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes | Q72398870 | ||
| Activation of extracellular signal-regulated protein kinases is associated with a sensitized locomotor response to D(2) dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats | Q73469669 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| P433 | issue | 1 | |
| P921 | main subject | cannabinoids | Q422936 |
| dyskinesia | Q629444 | ||
| striatum | Q1319792 | ||
| P304 | page(s) | 56-64 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Neurochemistry International | Q7002160 |
| P1476 | title | Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 | |
| P478 | volume | 54 |
| Q42087548 | A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease |
| Q35534149 | Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion |
| Q42121362 | Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors |
| Q34680801 | Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q42095959 | Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism |
| Q35209678 | Effects of endocannabinoid system modulation on cognitive and emotional behavior |
| Q48687516 | L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum |
| Q37794467 | Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. |
| Q48034195 | Lipid nanoparticles for administration of poorly water soluble neuroactive drugs. |
| Q35000569 | Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
| Q35683816 | Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats |
| Q28582782 | Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat |
| Q35740152 | The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q38223774 | The endocannabinoid system: a putative role in neurodegenerative diseases |
| Q48355383 | URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors |
Search more.